Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gaboxadol in Elderly Patients With Primary Insomnia
NCT00209924Phase 3Completed
- Sponsor
- Lundbeck
- Start
- Apr 2004
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of gaboxadol in Insomnia (3 arms), sponsored by Lundbeck. Primary endpoints: Wake After Sleep Onset at 4 weeks and Incidence of Treatment-Emergent Adverse Events at 4 weeks. Started Apr 2004; status: completed.
02
Drugs
gaboxadol
03
Conditions
Insomnia
Beyond the preview
Go deeper on NCT00209924.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00209924.